117486-132

Cytotoxic effect of euphol from Euphorbia tirucalli on a large panel of human cancer cell lines.

Category: 
Developmental Therapeutics - Clinical Pharmacology and Experimental Therapeutics
Session Type and Session Title: 
This abstract will not be presented at the 2013 ASCO Annual Meeting but has been published in conjunction with the meeting.
Abstract Number: 
e13557
Citation: 
J Clin Oncol 31, 2013 (suppl; abstr e13557)
Author(s): 
Rui Manuel Reis, Viviane Aline Oliveira Silva, Marcela Nunes Rosa, Aline Tansini, Joao Paulo Da S.N. Lima, Chris Jones, Luiz Francisco Pianowski; Barretos Cancer Hospital, Barretos, Brazil; Institute of Cancer Research, Sutton, United Kingdom; Pianowski & Pianowski LTDA, Bragança Paulista, Brazil

Abstracts that were granted an exception in accordance with ASCO's Conflict of Interest Policy are designated with a caret symbol (^).

Abstract Disclosures

Abstract: 

Background: The tetracyclic triterpene alcohol euphol is the main constituent found in the sap of Euphorbia tirucalli. In Brazil its latex is used as anticancer and other diseaseas folk treatment, yet, little is known about its anticancer proprieties. We aimed to study the antitumor effect of euphol on a large panel of human cancer cell lines. Methods: Anti-tumor effects of euphol in vitro were assessed using MTS assays on 77 human cancer lines from13 solid tumor models, such as breast, colon, bladder, prostate, lung, pancreas, esophagus, glioblastoma, melanoma, head and neck and cervical cancer. Additionally, we evaluate the its potential combinatorial value with temozolomide in gliomas. Ongoing experiments will identify potential drug target(s) by assessing changes in global protein expression. Results: Euphol exhibited dose and time-dependent cytotoxic effects on all cancer cell lines analyzed. Among each tumor type, the distinct cell line exhibited a heterogeneous profile of response to euphol. Esophageal squamous cell carcinoma and pancreatic carcinomas showed the most sensitive profile. In comparison with temozolomide, euphol showed a median of 30 fold higher efficacy, range 5-167 fold, in the glioma cell lines analyzed (Table). Conclusions: Euphol demonstrated potent anti-tumor activity on the majority of cancer cell lines evaluated. Our findings may provide insight into the tailoring designing of euphol-based therapies for cancer patients.

Cell line Tumor type Euphol IC50#
(µM, mean±SD)*
TMZ IC50#
(µM, mean±SD)*
U87-MG Adult glioma 28,24 ± 0,232 746,76 ± 3,15
U373 Adult glioma 30,48 ± 3,514 544,75 ±1,53
U251 Adult glioma 23,32 ± 2,177 696,4 ± 2,92
GAMG Adult glioma 8,473 ± 1,911 97 ± 2,05
SW1088 Adult glioma 27,41 ± 1,87 979,2 ± 4,00
SW1783 Adult glioma 19,62 ± 1,422 >1000
NHA Normal astrocytes 21,06 ± 4,157 110,5 ± 1,05
SNB19 Adult glioma 34,41 ± 0,943 >1000
RES186 Pediatric glioma 16,7 ± 3,722 714,75 ± 7,08
RES259 Pediatric glioma 9,834 ± 4,921 206,05 ± 6,09
KNS42 Pediatric glioma 24,07 ± 7,145 >1000
UW479 Pediatric glioma 15,26 ± 4,835 >1000
SF188 Pediatric glioma 5,983± 2,423 >1000

*Mean of at least three independent experiments; #Mean of the maximal (IC50) concentration cell lines; SD: Standard deviation.